Messenger RNA expression profiling of genes involved in epidermal growth factor receptor signalling in human cancer cells treated with scanning array-designed antisense oligonucleotides

Biochemical Pharmacology

Volumn 66, Issue 5, 2003, Pages 819-830

  Petch, Amelia K ^a   Sohail, Muhammad ^b   Hughes, Marcus D ^a   Benter, Ibrahim ^e   Darling, John ^c   Southern, Edwin M ^b   Akhtar, Saghir ^a,d  

^a ASTON UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e NONE

Author keywords

A431 cells; EGFR; Expression profiling; Glioma; Oligodeoxynucleotide; Phosphorothioate; Primary tumour; Signal transduction

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA;

ANALYTIC METHOD; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; GLIOMA CELL; HUMAN; HUMAN CELL; HYBRIDIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

EID: 0041428216     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00407-6     Document Type: Article

References (43)

1. Hughes M.D., Hussain M., Nawaz Q., Sayyed P., Akhtar S. Cellular delivery of antisense oligonucleotides and ribozymes. Drug Discov. Today. 6:2001;303-315.
2. Monia B.P., Johnston J.F., Geiger T., Muller M., Fabbro D. Antitumor-activity of a phosphorothioate antisense oligodeoxynucleotide targeted against c-raf kinase. Nature Med. 2:1996;668-675.
3. Ho S.P., Bao Y., Lesher T., Malhotra R., Ma L.Y., Fluharty S.J., Sakai R.R. Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nat. Biotechnol. 16:1998;59-63.
4. Sohail M., Hochegger H., Klotzbücher A., Le Guellec R., Hunt T., Southern E. Antisense oligonucleotides selected by hybridisation to scanning arrays are effective reagents in vivo. Nucleic Acids Res. 29:2001;2041-2051.
5. Akhtar S. Antisense technology: selection and delivery of optimally acting antisense oligonucleotides. J. Drug Target. 5:1998;225-234.
6. Monia B.P., Sasmor H., Johnston J.F., Freier S.M., Lesknik E.A., Muller M., Geiger T., Altmann K.H., Moser H., Fabbro D. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc. Natl. Acad. Sci. U.S.A. 93:1997;15481-15484.
7. Southern E.M., Milner N., Ku M. Discovering antisense reagents by hybridisation of RNA to oligonucleotide arrays. Ciba Found Symp. 209:1997;38-44. [discussion, 44-6].
8. Sohail M., Southern E.M. Oligonucleotide scanning arrays: application to high-throughput screening for effective antisense reagents and the study of nucleic acid interactions. Adv. Biochem. Eng. Biotechnol. 77:2002;43-56.
9. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2:2001;127-137.
10. Zwick E., Bange J., Ullrich A. Receptor tyrosine kinases as targets for anticancer drugs. Trend Mol. Med. 8:2002;17-23.
11. Lin S.Y., Makino K., Xia W., Matin A., Wen Y., Kwong K.Y., Bourguignon L., Hung M.C. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell Biol. 3:2001;802-808.
12. Arteaga C.L. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist. 7:2002;31-39.
13. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist. 7:2002;2-8.
14. Coulson J.M., Poyner D.R., Chantry A., Irwin W.J., Akhtar S. A non-antisense sequence-selective effect of a phosphorothioate oligonucleotide targeted to EGFR in A431 cells. Mol. Pharmacol. 50:1996;314-325.
15. Akhtar S., Dunnion D., Poyner D., Ackroyd J., Bibby M., Double J. Sequence and chemistry requirements for a novel aptameric oligonucleotide inhibitor of EGF receptor tyrosine kinase activity. Biochem. Pharmacol. 63:2002;2187-2195.
16. Wan M.S.K., Fell P.L., Akhtar S. 2′-O-Methyl-modified hammerhead ribozymes targeted to the RNA component of telomerase as sequence-specific inhibitors of telomerase activity. Antisense Nucleic Acid Drug Dev. 8:1998;309-317.
17. Southern E.M., Case-Green S.C., Elder J.K., Johnson M., Mir K.U., Wang L., Williams J.C. Arrays of complementary oligonucleotides for analysing the hybridisation behaviour of nucleic acids. Nucleic Acids Res. 22:1994;1368-1373.
18. Sohail M, Southern EM. Using oligonucleotide scanning arrays to find effective antisense reagents. In: Pampal JB, editor. Methods in molecular biology - oligonucleotide array methods and protocols. Totowa, NJ: Humana Press; 2001.
19. Islam A., Handley S.L., Thompson K.S.J., Akhtar S. Studies on uptake, sub-cellular trafficking and efflux of antisense oligodeoxynucleotides in glioma cells using self-assembling cationic lipoplexes as delivery systems. J. Drug Target. 7:2000;373-382.
20. Sohail M., Akhtar S., Southern E.M. The folding of large RNAs studied by hybridisation to arrays of complementary oligonucleotides. RNA. 5:1999;646-655.
21. Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The ErbB signalling network: receptor heterodimerization in development and cancer. EMBO J. 19:2000;3159-3167.
22. Fazioli F., Minichiello L., Matoskova B., Wong W.T., Di Fiore P.P. Eps 15, a novel tyrosine kinase substrate, exhibits transforming activity. Mol. Cell. Biol. 13:1993;5814-5828.
23. Levkowitz G., Klapper L.N., Tzahar E., Freywald A., Sela M., Yarden Y. Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins. Oncogene. 12:1996;117-125.
24. Torrisi M.R., Lotti L.V., Belleudi F., Gradini R., Salcini A.E., Confalonieri S., Pelicci P.G., Di Fiore P.P. Eps15 is recruited to the plasma membrane upon epidermal growth factor receptor activation and localizes to components of the endocytic pathway during receptor internalisation. Mol. Biol. Cell. 10:1999;417-434.
25. Lanzetti L., Rybin V., Malabarba M.G., Christoforidis S., Scita G., Zerial M., Di Fiore P.P. The Eps8 protein coordinates EGF receptor signalling through Rac and trafficking through Rab5a. Nature. 408:2000;374-377.
26. Hornia A., Lu Z., Sukezane T., Zhong M., Joseph T., Frankel P., Foster D.A. Antagonistic effects of protein kinase C α and δ on both transformation and phospholipase D activity mediated by the epidermal growth factor receptor. Mol. Cell. Biol. 19:1999;7672-7680.
27. Yeo E.J., Exton J.H. Stimulation of phospholipase D by epidermal growth factor requires protein kinase C activation in Swiss 3T3 cells. Biol. Chem. 270:1995;3980-3988.
28. O'dwyer P.J., Benson A.B. III Epidermal growth factor receptor-targeted therapy in colorectal cancer. Semin. Oncol. 5:2002;10-17.
29. Chan T.O., Rittenhouse S.E., Tsichlis P.N. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu. Rev. Biochem. 68:1999;965-1014.
30. Cho Y.S., Kim M.K., Cheadle C., Neary C., Becker K.G., Cho-Chung Y.S. Antisense DNAs as multisite genomic modulators identified by DNA microarray. Proc. Natl. Acad. Sci. U.S.A. 98:2001;9819-9823.
31. Astriab-Fisher A., Ye D., Sergueev D., Fisher M., Shaw B.R., Juliano R.L. Evaluating the specificity of antisense oligonucleotide conjugates. A DNA array analysis. J. Biol. Chem. 277(25):2002;22980-22984.
32. Coulson J.M., Akhtar S. A c-myc phosphorothioate oligonucleotide protects U87-MG glioblastoma cells from toxicity at high concentrations of lipofectin and streptolysin-O. Pharm. Sci. 3:1997;197-201.
33. Rockwell P., O'Connor W.J., King K., Goldstein N.I., Zhang L.M., Stein C.A. Cell-surface perturbations of the epidermal growth factor receptors by phosphorothioate oligodeoxynucleotides. Proc. Natl. Acad. Sci. U.S.A. 94:1997;6523-6524.
34. Rubin Grandis J., Chakraborty A., Melhem M.F., Zeng Q., Tweardy D.J. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogene. 15:1997;409-416.
35. Witters L., Kumar R., Mandal M., Bennett C.F., Miraglia L., Lipton A. Antisense oligonucleotides to the epidermal growth factor receptor. Breast Cancer Res. Treat. 53:1999;41-50.
36. Ciardiello F., Caputo R., Troiani T., Borriello G., Kandimalla E.R., Agrawal S., Mendelsohn J., Bianco A.R., Tortora G. Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis and cooperate with cytotoxic drugs in human cancer cell lines. Int. J. Cancer. 93:2001;172-178.
37. Rubenstein M., Glick R., Lichtor T., Mirochnik Y., Chou P., Guinan P. Treatment of the T98G glioblastoma cell line with antisense oligonucleotides directed toward mRNA encoding transforming growth factor-alpha and the epidermal growth factor receptor. Med. Oncol. 18:2001;121-130.
38. Akhtar S., Hughes M.D., Khan A., Bibby M., Hussain M., Nawaz Q., Double J., Sayyed P. The delivery of antisense therapeutics. Adv. Drug Deliv. 44:2000;3-21.
39. Sohail M., Southern E.M. Antisense arrays. Mol. Cell. Biol. Res. Commun. 3:2000;67-72.
40. Milner N., Mir K.U., Southern E.M. Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nat. Biotechnol. 15:1997;537-541.
41. Mir K.U., Southern E.M. Determining the influence of structure on hybridisation using oligonucleotide arrays. Nat. Biotechnol. 17:1999;788-792.
42. Hochegger H., Klotzbucher A., Kirk J., Howell M., Le Guellec K., Fletcher K., Duncan T., Sohail M., Hunt T. New B-type cyclin synthesis is required between meiosis I and II during Xenopus oocyte maturation. Development. 128:2001;3795-3807.
43. Modjtahedi H., Dean C. The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer [review]. Int. J. Oncol. 4:1994;277-296.